Cyberknife Radiosurgery in Hepatocellular carcinoma with Portal vein tumor thrombosis
- Conditions
- Health Condition 1: C220- Liver cell carcinoma
- Registration Number
- CTRI/2022/02/040384
- Lead Sponsor
- Amrita Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients with radiologically confirmed HCC with
portal vein invasion, willing to participate in the study, having good performance statusâ??Eastern Cooperative Oncology Group (ECOG)â??0 to 2 preserved liver function (bilirubin <4 mg/dL, preferably albumin >3 g/dL, international normalized ratio [INR] < 1.5) no (or mild) ascites, not suitable for TACE, and age above 18 years.
Patients not consenting for the study, poor performance status (ECOG 3â??4), extrahepatic visceral metastases, long PVT involvement ( >7 cm in axial length), Child C with decompensated liver function, large HCC ( >10 cm cumulative length of the mass), and previously treated with radiation therapy for liver lesion and patients who underwent transarterial radioembolization (TARE).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment with recanalization of portal veinTimepoint: 10 weeks
- Secondary Outcome Measures
Name Time Method survival function, toxicity parameters, factors influencing <br/ ><br>response to treatment, and feasibility of TACE/TARE in <br/ ><br>responders.Timepoint: 6 months, 1 year, 2 year